The Claim
Tirzepatide reduces the risk of coronary revascularization by 16% compared to dulaglutide in adults with type 2 diabetes and established cardiovascular disease over a median follow-up of 47 months, with a hazard ratio of 0.84 (95% CI, 0.75–0.95).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and existing heart disease, tirzepatide is associated with a lower rate of procedures to reopen blocked heart arteries compared to dulaglutide, based on a study following patients for about 4 years.
See the scientific wording
Tirzepatide reduces the risk of coronary revascularization by 16% compared to dulaglutide in adults with type 2 diabetes and established cardiovascular disease over a median follow-up of 47 months, with a hazard ratio of 0.84 (95% CI, 0.75–0.95).
Tirzepatide helps the body use sugar and fat better, which lowers harmful fats and inflammation in the blood. This makes the fatty buildups in heart arteries less likely to grow or break open, so fewer blockages form that need stents or bypass surgery.
What the research says
1 studyIn people with type 2 diabetes and heart disease, tirzepatide was shown to lower the chance of needing heart procedures like stents or bypass surgery by about 16% compared to another common diabetes drug, dulaglutide, over about four years.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.